Phosphorylation of Two Serine Residues Regulates Human T-Cell Leukemia Virus Type 2 Rex Function

MURLI NARAYAN,^{1,2,3} KOICHI KUSUHARA,⁴ AND PATRICK L. GREEN^{1,2,3,5,6*}

*Departments of Veterinary Biosciences*¹ *and Molecular Virology, Immunology, and Medical Genetics,*⁵ *Center for Retrovirus Research,*² *Comprehensive Cancer Center,*⁶ *and Ohio State Biochemistry Program,*³ *The Ohio State University, Columbus, Ohio 43210, and Department of Pediatrics, Faculty of Medicine, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan*⁴

Received 14 February 2001/Accepted 8 June 2001

The function of the human T-cell leukemia virus (HTLV) Rex phosphoprotein is to increase the level of the viral structural and enzymatic gene products expressed from the incompletely spliced viral RNAs containing the Rex-responsive element. The phosphorylation of HTLV type 2 Rex (Rex-2), predominantly on serine residues, correlates with an altered conformation, as detected by a gel mobility shift, and is required for specific binding to its viral RNA target sequence. Thus, the phosphorylation state of Rex in the infected cell may be a switch that determines whether the virus exists in a latent or a productive state. A mutational analysis of Rex-2 that focused on serine and threonine residues was performed to identify regions or domains within Rex-2 important for function, with a specific emphasis on identifying Rex-2 phosphorylation mutants. We identified mutations near the carboxy terminus that disrupted a novel region or domain and abrogated Rex-2 function. Mutant M17 (with S151A and S153A mutations) displayed reduced phosphorylation that correlated with reduced function. Replacement of both serine residues 151 and 153 with phosphomimetic aspartic acid restored Rex-2 function and locked Rex-2 in a phosphorylated active conformation. A mutant containing threonine residues at positions 151 and 153 displayed a phenotype indistinguishable from that of wild-type Rex. Furthermore, this same mutant showed increased threonine phosphorylation and decreased serine phosphorylation, providing conclusive evidence that one or both of these residues are phosphorylated in vivo. Our results provide the first direct evidence that the phosphorylation of Rex-2 is important for function. Further understanding of HTLV Rex phosphorylation will provide insight into the regulatory control of HTLV replication and ultimately the pathobiology of HTLV.

Human T-cell leukemia virus (HTLV) types 1 (HTLV-1) and 2 (HTLV-2) are complex retroviruses that have been causally associated with leukemia and neurological disorders in humans (21). In addition to structural and enzymatic genes *gag*, *pol*, and *env*, HTLV encodes two *trans-*acting regulatory gene products, Tax and Rex, both of which are essential for viral replication (15, 17, 24). Tax acts to increase the rate of transcription from the viral long terminal repeat (LTR). In addition, Tax modulates the transcription of various cellular genes involved in growth and differentiation and disrupts cell cycle control and DNA repair processes (3, 4, 38, 45, 47). These pleiotropic effects of Tax on cellular processes are likely important in the ability of HTLV to mediate oncogenesis. Consistent with this hypothesis, Tax was recently shown to be essential for cellular transformation of primary human T lymphocytes in cultures (39, 41).

Rex, the other *trans-*acting regulatory protein, specifically binds unspliced and singly spliced viral RNAs, resulting in RNA stabilization and their selective trafficking to the cytoplasm (6, 30). These RNAs encode viral structural and enzymatic gene products. Rex function is mediated by a *cis*-acting RNA sequence, termed the Rex-responsive element (RxRE), located in the R region of the viral LTR (6, 9, 13, 20, 27, 35). Several functional domains of Rex have been identified to

* Corresponding author. Mailing address: The Ohio State University, 1925 Coffey Rd., Columbus, OH 43210. Phone: (614) 688-4899. Fax: (614) 292-6473. E-mail: green.466@osu.edu.

date. A highly basic amino acid sequence at the amino terminus of HTLV-1 Rex (Rex-1) and HTLV-2 Rex (Rex-2) is required for RNA binding and subcellular targeting to the nucleus or nucleolus (25, 34, 43). Both Rex-1 and Rex-2 have a leucine-rich activation domain that is required for interaction with cellular factors, including the human nucleoporin-like Rev/Rex activation domain binding protein (Rab) and human Rev interactive protein (hRIP) cofactors involved in nuclear export (18, 33). Recently, this activation domain was also shown to encompass a nuclear export signal (NES) and to be indispensable for Rex function (37). Mutational and chemical analyses of Rex-1 and the functionally analogous human immunodeficiency virus (HIV) type 1 (HIV-1) Rev implicated a third domain, responsible for multimerization of these proteins. Although the exact nature of multimerization is debatable, it has been suggested that multimerization is critical for Rex and HIV-1 Rev function (12, 26, 31, 36).

Two forms of Rex-2, p24*rex* and p26*rex*, are detected in HTLV-2-infected T cells (40, 42). Both species of Rex-2 have also been detected in cell lines transfected with *rex* expression plasmids; these include 729 human B cells, SF9 insect cells, COS cells, and JM4 human T cells (22–24, 40, 49). A previous study indicated that p24*rex* and p26*rex* share the same amino acid backbone and that they differ in the extent of serine phosphorylation (23). Thus, p26*rex* is the result of an altered conformation induced by the phosphorylation of a subset of serine residues. Similarly, Rex-1 is phosphorylated on serine, but phosphorylation does not result in significant altered gel

mobility (1). Immunofluorescence studies have shown that p24*rex* is present only in the cytoplasm, whereas the phosphorylated form, p26*rex*, is predominantly localized in the nucleus and nucleolus (16). Biochemical studies have indicated that the phosphorylated form of Rex-2, p26*rex*, binds RxRE-containing RNA and thus is biologically active (24). Interestingly, Tax has been shown to be phosphorylated on a serine residue(s). One study suggested that the phosphorylation of either serine 300 or serine 301 is required for localization to nuclear bodies and Tax-mediated activation of gene expression (8). Another study identified serine-to-alanine mutations important for Tax transactivation function, but these serine residues were not phosphorylated (11). The precise role of phosphorylation in the regulation of either Rex or Tax function has not yet been determined.

In this study, a mutational analysis of Rex-2 targeting serine and threonine residues was performed to identify regions or domains within Rex-2 important for function, with a specific emphasis on identifying Rex-2 phosphorylation mutants. In addition to identifying mutations that disrupt the RNA binding-nuclear localization domain, the activation-effector-NES domain, and the multimerization domain, we identified a novel region or domain at the carboxy terminus that is important for Rex-2 function. One of the C-terminal mutants (with S151A and S153A mutations [S151A,S153A]) displayed a reduction in the p26 phosphorylated conformation of Rex that also correlated with reduced Rex function. Replacement of both serine residues 151 and 153 with aspartic acid locked Rex-2 in a phosphorylated active state and restored Rex-2 function. Twodimensional (2D) phosphoamino acid analysis of a Rex-2 mutant containing threonine residues at positions 151 and 153 revealed decreased serine phosphorylation in conjunction with increased threonine phosphorylation, providing further evidence of in vivo phosphorylation of these residues. Our data provide the first direct evidence that the phosphorylation of critical residues at the carboxy terminus of Rex-2 is critical for function. Further understanding of HTLV Rex phosphorylation will provide insight into the regulatory control of HTLV replication and ultimately HTLV pathogenesis.

MATERIALS AND METHODS

Cells. 293 T cells were maintained in Dulbecco modified Eagle medium (DMEM) supplemented to contain 10% fetal calf serum, penicillin (100 U/ml), streptomycin (100 μ g/ml), and 2 mM glutamine.

Plasmids. Rex expression vector BC20.2, containing HTLV-2 *tax*/*rex* cDNA expressed from the cytomegalovirus (CMV) immediate-early gene promoter, has been described earlier (14, 23). Various *rex* mutants were generated by sitedirected mutagenesis (with Quick Change; Stratagene) using BC20.2 as a template. Mutations were confirmed by dideoxy DNA sequencing. HIV-1 Tat expression vector pctat contains HIV-1 *tat* cDNA cloned downstream of the CMV promoter. Reporter pCgagRxRE-II (a kind gift from Vincenzo Ciminale, University of Padua, Padua, Italy) contains the HIV-1 LTR promoter and *gag* gene linked to a 445-bp fragment of HTLV-2 spanning the RxRE (nucleotides 316 to 760 of the R-U5 region) (16). A CMV-luciferase plasmid was used to control for transfection efficiency in each experiment (luciferase assay system; Promega).

Transfection and p24*gag* **enzyme-linked immunosorbent assay.** Wild-type *rex* or various *rex* mutant expression plasmids were introduced into 293 T cells using the calcium phosphate transfection protocol. Briefly, 2×10^5 cells were transfected with 1μ g of pctat, 3μ g of pCgagRxRE-II, 1μ g of CMV-luciferase plasmid, and 5 μ g of wild-type *rex* or various *rex* mutant expression plasmids or negative control. Cell lysates were made 48 h posttransfection using lysis buffer, containing 100 mM Tris (pH 7.6) and 0.5% Triton X-100. Luciferase activity for each sample was determined to control for transfection efficiency. HIV-1 p24*gag* levels in cell lysates were determined using a p24*gag* enzyme-linked immunosorbent assay (p24 HIV antigen assay kit; Beckman-Coulter). p24*gag* calibration curves were generated using HIV-1 p24 antigen standards as described by the kit manufacturer; the detection sensitivity was 1 pg/ml. All the experiments were performed in triplicate and normalized for transfection efficiency. Statistical significance relative to results for wild-type Rex was determined by the Student *t* test.

Metabolic labeling and immunoprecipitation. Twenty-five micrograms of wildtype *rex* or various *rex* mutant expression plasmids or negative control was electroporated into 5×10^6 293 T cells (975 μ F and 250 V). Cells were metabolically labeled 24 h posttransfection with [³⁵S]methionine-[³⁵S]cysteine (Trans-35S-label, 100 mCi/ml; Amersham) in methionine-cysteine-free RPMI 1640 supplemented with 20% dialyzed fetal calf serum. Cells were lysed in immunoprecipitation buffer (0.05 M Tris [pH 8.0], 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-100, 0.15 M NaCl, 2 mM phenylmethylsulfonyl fluoride, 1 µg of leupeptin/ml, $1 \mu g$ of pepstatin A/ml), and the lysates were clarified by centrifugation at 17,000 \times g for 30 min at 4°C. The lysates were subsequently immunoprecipitated using anti-Rex antiserum (directed against C-terminal amino acid residues 139 to 170) for 16 h at 4°C. Protein A–Sepharose CL-4B (Sigma) was used to collect the immune complexes. Proteins were directly electrophoresed on an SDS–10% polyacrylamide gel; alternatively, for in vitro dephosphorylation experiments, prior to electrophoresis the immune complexes were incubated with 600 U of bacterial alkaline phosphatase (BAP) (GIBCO BRL) for 3 h at 65°C in 50 µl of BAP buffer, containing 50 mM NaCl, 10 mM Tris-Cl (pH 8.0), and 10 mM $MgCl₂$. ³⁵S-labeled proteins were visualized by autoradiography and quantified by PhosphorImager analysis (Molecular Dynamics).

2D phosphoamino acid analysis. 293 T cells (5×10^6) were electroporated with 25 mg of wild-type *rex* expression plasmid BC20.2 or *rex* mutant S151T,S153T at 975 μ F and 250 V. At 24 h posttransfection, cells were metabolically labeled with 2 mCi of ${}^{32}P_i/ml$, and cell lysates were prepared as described above. p26*rex* phosphorylated in vivo was resolved on an SDS–10% polyacrylamide gel, transferred to an Immobilon-P membrane (Millipore), and detected by autoradiography. Samples were prepared and 2D phosphoamino acid analysis was performed as previously described. Briefly, membrane pieces containing phosphorylated p26*rex* were incubated in 0.5% polyvinylpyrrolidone in 100 mM acetic acid for 30 min at 37°C. The membrane was then washed three times in H_2O and subjected to hydrolysis using 5.7 M HCl at 110°C for 60 min. The supernatant containing the hydrolyzed amino acids was centrifuged at $17,000 \times g$ for 10 min, washed by repeated lyophilization, and subjected to 2D phosphoamino acid analysis using a thin-layer electrophoresis system (HTLE-7000; CBS Scientific, Del Mar, Calif.). The hydrolyzed amino acids were applied to thin-layer cellulose plates along with phosphorylated Ser (p-Ser), p-Thr, and a p-Tyr standards at 0.5 μ g each per μ l; electrophoresed at pH 1.9 for 25 min at 1.0 kV (\sim 13 mA) in the first dimension; and then subjected to electrophoresis in the second dimension at pH 3.5 for 20 min at 1.5 V (\sim 16 mA). Amino acid standards were visualized by staining with 0.25% ninhydrin in acetone, and the radiolabeled amino acids were visualized by direct autoradiography and quantified by PhosphorImager analysis.

RESULTS

Generation of Rex-2 mutants. The phosphorylation of Rex-2 primarily on serine residues has been shown to be critical for functional RNA binding (23, 24). The 170-amino-acid Rex-2 protein contains 25 serine and 12 threonine residues that are potential phosphorylation sites. Our objective was to introduce mutations throughout the wild-type *rex-2* expression plasmid, BC20.2, which would cause the substitution of alanine for serine or threonine residues. Based on previous reports and on alignment with Rex-1, several of our mutations were predicted to occur in the RNA binding region or nuclear localization domain (amino acids 1 to 19), activation-effector domain containing the overlapping NES (amino acids 81 to 94), and multimerization domain (amino acids 57 to 66 and 106 to 124). In all, 19 Rex-2 mutants were generated consisting of 6 single amino acid substitutions, 9 double amino acid substitutions, and 4 triple amino acid changes. Figure 1A shows the alignment of Rex-1 and Rex-2 and the previously identified do-

FIG. 1. (A) Amino acid alignment of Rex-1 (top) and Rex-2 (bottom). Identities are indicated by double dots, and similarities are indicated by single dots. Rex-2 is 19 amino acid residues shorter than Rex-1. Rex-1 domains, including the nuclear localization (NLS)-RNA binding (25, 34, 43), multimerization, and activation-effector domains, are indicated (12, 25, 31, 34, 43). The locations of the Rex-2 mutants are indicated. (B) Summary of all mutations (M1 to M19).

 $M19$

mains. Figure 1B shows the predicted amino acid substitutions in our panel of mutants.

M9

 $M10$

S88A, T90A

S92A, S95A

Expression of Rex-2 mutants. The stable expression of the various Rex-2 mutants from metabolically labeled 293 T cells was determined by radioimmunoprecipitation and SDS-polyacrylamide gel electrophoresis (PAGE) using anti-Rex-2 peptide antiserum. As expected, in cells transfected with our wildtype *rex-2* expression construct, the p24*rex* form and the phosphorylated p26*rex* conformation were detected (Fig. 2). All of the Rex-2 mutants appeared to be stably expressed. With the exception of M9, all of the mutants displayed both forms of the Rex protein. To determine if there were significant differences in the levels of p26*rex* and p24*rex*, we quantitated their amounts over four independent experiments; the results are summarized as an average p26*rex*/p24*rex* ratio below each lane of Fig. 2. The majority of the mutants displayed ratios similar to that of wild-type Rex (a p26*rex*/p24*rex* ratio of nearly 1). Interestingly, a mutant with a mutation at the carboxy terminus, M17 (S151A,S153A), showed a significant reduction in the amount of p26*rex* in multiple experiments, with an average p26*rex*/p24*rex* ratio of 0.54 (Fig. 2, lane M17; see also Fig. 4 and 7B). These results suggest that residues 151 and/or 153 might be important for protein modification and/or conformation.

T162A, S163A, T164A

Rex-2 mutants segregate into four functional regions or domains. Our series of Rex-2 mutants were tested for their ability to function in a quantitative bioassay using reporter plasmid pCgagRxRE-II. This plasmid contains the HIV-1 LTR and *gag* gene linked to the RxRE of HTLV-2 and the simian

FIG. 2. Detection of Rex-2 mutants in 293 T cells. 293 T cells were transfected with 25 µg of wild-type (Wt) or various rex mutant expression vectors or vector alone (control). At 24 h posttransfection, cells were metabolically labeled using [³⁵S]methionine-[³⁵S]cysteine; cell lysates were made as described in Materials and Methods. Lysates were immunoprecipitated using anti-Rex antiserum in the presence of protein A-Sepharose. Immunoprecipitated proteins were fractionated by SDS-PAGE and visualized by autoradiography. 14C low-molecular-mass markers are indicated on the left (lane M). The results indicate that all of the Rex mutants are efficiently expressed in 293 T cells. $p26^{rex}$ and $p24^{rex}$ were quantitated by PhosphorImager analysis over four independent experiments, and values were averaged. The p26*rex*/p24*rex* ratio is presented below each lane. (Note that M17 displays a significant reproducible reduction in the level of p26*rex*.)

virus 40 polyadenylation signal or site (16). Efficient expression of Gag is dependent on Tat-mediated transcription and functional Rex binding to RxRE sequences. 293 T cells were cotransfected with pctat, pCgagRxRE-II, and wild-type or mutant *rex* expression vectors or negative control, and p24*gag* production was monitored using a Gag antigen capture assay. To test the sensitivity of this system, we performed a titration with increasing concentrations of *rex* expression plasmid, keeping the concentrations of pctat and pCgagRxRE II constant. We did not see any significant difference in p24*gag* values at concentrations between 1 and 5 mg of *rex* plasmid (data not shown). Therefore, all the subsequent experiments were performed with 5 mg of *rex* expression plasmid (saturating concentration of *rex* expression plasmid).

Our analysis revealed functionally deficient Rex-2 mutants clustering in four regions or domains (Fig. 3). Mutant M1, with mutations within the amino-terminal RNA binding-nuclear localization domain, showed p24*gag* levels 50% those in our reporter assay. Mutants M9 and M10, with mutations within the effector-activation domain (also containing the overlapping NES), showed drastic reductions in p24*gag* production compared to wild-type Rex-2. Previous studies have shown that the activation domain or effector domain is required for various protein-protein interactions and is indispensable for Rex-1 and Rex-2 function (18, 37). Mutants M5 and M14 exhibited significant reductions in p24*gag* levels compared to wild-type Rex-2. Amino acid alignment of Rex-1 and Rex-2 suggested that these mutations are within the multimerization domain identified for Rex-1. Previous work has suggested that multimerization is required for Rex-1 function (12, 48). Therefore, it would appear that a similar domain is present in Rex-2 and that multimerization is required for function.

M16, M17, M18, and M19, containing carboxy-terminal mutations, displayed approximately 25 to 40% the activity of wildtype Rex. The majority of functionally deficient mutants had p26*rex*/p24*rex* ratios similar to that of wild-type Rex, with the

FIG. 3. Rex-2 functional assay. 293 T cells (2×10^5) were transfected with 1 µg of pctat, 3 µg of pCgagRxRE-II, 1 µg of luciferase, and 5 µg of wild-type (Wt) or various *rex* mutant expression vectors or vector alone (C). At 48 h posttransfection, cells were harvested and assayed for p24*gag* as described in Materials and Methods. Lysates were assayed for luciferase activity to control for transfection efficiency. The values, which represent relative p24*gag* levels for three independent experiments, are normalized to the value for Wt *rex* (set as 1). Error bars indicate standard deviations. Significance relative to the results for Wt Rex was determined by the Student *t* test; values that are statistically different are indicated by asterisks. The data suggest that functionally deficient Rex-2 mutants segregate into four groups.

FIG. 4. Detection of Rex-2 phosphorylation mutants in 293 T cells. Transfection, immunoprecipitation, and SDS-PAGE analysis were performed as described in the legend to Fig. 2. Wild-type (Wt) Rex, various Rex mutants, and the control are indicated. The data indicate that serines 151 and 153 are required for the phosphorylation-induced mobility shift from p24*rex* to p26*rex* and that replacement of either one or both serines 151 and 153 with aspartic acid locks the protein in a phosphorylated conformation. Lane M, markers.

exception of M17. Although our results suggest a novel functional domain located at the carboxy terminus, we focused the remainder of our study on residues 151 and 153 because the reduction in M17 activity or function correlated with altered mobility or, more specifically, a reduction in the amount of phosphorylated p26*rex*.

Phosphomimetic substitutions at serine 151 and serine 153 lock Rex in a p26 functional state. To test the hypothesis that serines 151 and 153 are residues that are phosphorylated and critical for function, the serine residues were mutated either individually or in combination to alanine and/or aspartic acid to mimic phosphoserine. We first investigated the expression and mobility of these mutants by SDS-PAGE. Interestingly, aspartic acid residues at positions 151 and/or 153 migrated as a single 26-kDa band (p26*rex*) with no detectable p24*rex* (Fig. 4). This result indicates that the replacement of serine at position 151 or 153 by aspartic acid appears to lock the protein in a phosphorylated state or conformation. We next tested the aspartic acid mutants in the Rex functional reporter assay. The results indicate that all three aspartic acid mutants are fully functional (Fig. 5). Together, these results further support the notion that the phosphorylated p26*rex* conformation is the active form of Rex and suggest that modification of residues 151 and/or 153 contributes to this conformation and activity.

If the level of p26*rex* correlates with function, then one might expect that since the aspartic acid mutants with mutations at positions 151 and/or 153 are found exclusively in the phosphorylated p26^{rex} active conformation, these mutants should show higher levels of functional activity than wild-type Rex. To test

FIG. 5. Rex-2 functional assay for phosphorylation mutants. The Rex functional assay was performed as described in the legend to Fig. 3. Wild-type (Wt) Rex, various Rex mutants, and the control are indicated. Error bars indicate standard deviations. Significance relative to the results for Wt Rex was determined by the Student *t* test; a value that is statistically different is indicated by an asterisk. The results suggest that serines 151 and 153 are necessary for function and that replacement of these sites with a phosphomimetic amino acid restores the activity to Wt levels.

this hypothesis, the activities of wild-type Rex and the M17 (S151A,S153A) and S151D,S153D double mutants were assessed by use of the Gag reporter assay with increasing DNA concentrations of wild-type and *rex* mutant plasmids. Our results indicate that the activity of M17 (S151A,S153A) is approximately 25 to 30% that of wild-type Rex over a range of *rex* expression plasmid concentrations (0.1 to 5 μ g), whereas S151D,S153D is significantly more active at the lowest concentration tested; this difference is gradually lost and disappears at higher concentrations (Fig. 6). Taken together, these results are consistent with the conclusion that the phosphorylation of

FIG. 6. The S151D,S153D mutant is more active than wild-type Rex. 293 T cells (2×10^5) were transfected with 1 µg of pctat, 3 µg of $pCgagRxRE-II, 1 µg$ of luciferase, and increasing concentrations (0.1 to $\overline{5}$ μ g) of wild-type (WT) or *rex* mutant (M17 [S151A,S153A] or S151D,S153D) expression vectors. At 48 h posttransfection, cells were harvested and assayed for p24*gag* as described in Materials and Methods. Lysates were assayed for luciferase activity to control for transfection efficiency. The values represent actual p24*gag* levels for three independent experiments. Error bars indicate standard deviations. The results indicate that at lower DNA concentrations, Rex mutant S151D,S153D (exclusively in the p26*rex* conformation) is significantly more active than WT Rex.

serines 151 and/or 153 of Rex-2 results in a hyperphosphorylated and biologically functional Rex protein (p26*rex*).

We next determined whether phosphorylation at some other site was responsible or required for maintaining the aspartic acid mutant with mutations at positions 151 and 153 exclusively in the p26*rex* conformation. The S151D,S153D mutant protein was subjected to BAP treatment in vitro. As previously reported (24), BAP treatment of wild-type Rex-2 resulted in the loss of p26*rex* and a concomitant increase in the amount of p24*rex* (Fig. 7A). However, BAP treatment had no effect on the mobility of the S151D,S153D p26*rex* mutant (Fig. 7A). These results provide further evidence that phosphomimetic aspartic acid at positions 151 and 153 locks the protein in a phosphorylated active conformation. Similar analysis of the M17 mutant (S151A,S153A) indicated that the reduced or remaining amount of p26*rex* was subject to loss following BAP treatment (Fig. 7B). These results indicate that the phosphorylation of an additional site(s) leads to the conformational change and further suggest that the phosphorylation of residues 151 and/or 153 likely stabilizes that conformation.

To investigate the individual contributions of serines 151 and 153 to the phosphorylation-induced conformational change and Rex-2 function, we made single amino acid changes at either position 151 or position153 by mutating the amino acid to either alanine or aspartic acid. SDS gel analysis of the S151A mutant shows a predominant p24*rex* form and a reduced p26*rex* form, similar to the results obtained with the alanine double mutant M17. The S153A mutant shows equal levels of p24*rex* and p26*rex*, similar to those seen with wild-type Rex (Fig. 8). These results suggest that serine 151 plays a greater role than serine 153 in the phosphorylation-induced mobility change on the SDS gel. Functional analyses of these mutants are consistent with the level of p26*rex*. S151A shows a significant reduction in activity, whereas S153A function is similar to that of wild-type Rex (Fig. 9). Interestingly, replacement of either serine 151 or serine 153 with aspartic acid is capable of locking the protein in a phosphorylated state, as measured by decreased mobility (Fig. 8). BAP treatment of both the S151D and the S153D mutants did not result in the loss of p26*rex* (data not shown). In addition, double mutants (S151A,S153D and S151D,S153A) are fully functional and migrate as a single p26*rex* species (Fig. 4 and 5). Taken together, these data indicate that aspartic acid at either or both residues 151 and 153 is sufficient to lock the protein in the p26*rex* conformation, consistent with a phosphorylated state. However, when tested alone, residue 151 appears to play a more significant role.

Serine 151 and serine 153 are critical phosphorylation sites. We next directly evaluated whether residues 151 and 153 are truly phosphorylated in vivo. Earlier studies had shown that Rex-2 is phosphorylated predominantly on serine residues (23). Therefore, if these residues are phosphorylated, replacement of serines 151 and 153 with threonine should result in increased threonine phosphorylation in conjunction with decreased serine phosphorylation. SDS gel and functional analyses of the S151T,S153T mutant revealed that its mobility and functional activity are similar to those of wild-type Rex-2, suggesting that threonine at these residues can efficiently substitute for serine (data not shown).

We next performed 2D phosphoamino acid analysis of the

S151T,S153T mutant and wild-type Rex. We found a clear increase in threonine phosphorylation (Fig. 10). PhosphorImager analysis indicates that this increased threonine phosphorylation in the S151T,S153T mutant coincides with a 70% reduction in serine phosphorylation compared to the results for wild-type Rex. This finding provides direct evidence that residues 151 and/or 153 are phosphorylated in vivo. Interestingly, the S151T,S153T mutant still retained some serine phosphorylation, indicating that there is an additional serine(s) phosphorylated on Rex-2. This finding is consistent with the results of the BAP experiments shown in Fig. 7B, in which M17 still contained phosphorylated residues that contributed to the p24*rex*-to-p26*rex* conformational change. However, mutation of serine residues 151 and/or 153, either preventing phosphorylation or mimicking phosphoserine, has a direct effect on Rex-2 mobility or conformation and function.

DISCUSSION

It was previously demonstrated that phosphorylation of HTLV-2 Rex is required for efficient binding to viral target RNAs containing the RxRE (24). In this study, we subjected HTLV-2 Rex to mutational analysis to identify functional domains, with specific emphasis on identifying Rex-2 phosphorylation mutants. We identified four distinct groups of functionally deficient Rex-2 mutants. In addition to identifying mutants that disrupt the RNA binding-nuclear localization domain, the activation-effector domain (also containing the overlapping NES), and the multimerization domain, we identified a novel region or domain at the carboxy terminus that disrupts Rex-2 function. One carboxy-terminal mutant (S151A,S153A) displayed reduced phosphorylation that correlated with reduced function. Our further analysis indicated that serine residues 151 and/or 153 are phosphorylated in vivo and that this phosphorylation is likely critical to maintain Rex-2 in an active conformation required for efficient function.

It has been well documented that posttranslational modification of proteins by phosphorylation affects protein conformation and/or function. For example, a mobility change detected by SDS-PAGE analysis of the *fos* nuclear oncoprotein (7), polyomavirus large T antigen (10), and adenovirus E1A (44) results from phosphorylation on one or more serine residues. It has been hypothesized that this mobility shift is likely due to a change in protein structure which might be critical for protein function. Interestingly, a recent study investigating the signaling protein nitrogen regulatory protein C (NtrC) revealed that activation by phosphorylation involved stabilization of a preexisting condition or conformation. Nuclear magnetic resonance measurements indicated that phosphorylation shifted the equilibrium of NtrC far toward the active conformation (46).

A previous study indicated that p26*rex* is a phosphorylated form of p24*rex* and that phosphorylation on serine residues is critical for its ability to specifically bind RxRE-containing RNA (24). In addition, it has been shown that the phosphorylated form of Rex-2 is required to inhibit RNA splicing reactions in vitro (5). Thus, the p26*rex* phosphorylated form is the active form which would be required for HTLV to be in the productive phase of viral replication. In HTLV-infected cells, both phosphorylated and nonphosphorylated forms of Rex are

FIG. 7. In vitro dephosphorylation of wild-type Rex-2, the S151D,S153D mutant, and mutant M17. (A) 293 T cells were transfected with 25 mg of wild-type (Wt) or *rex* mutant (S151D,S153D) expression vector. At 24 h posttransfection, cells were metabolically labeled using [³⁵S]methionine-[³⁵S]cysteine, and cell lysates were made as described in Materials and Methods. Transfected cell lysates were immunoprecipitated using anti-Rex-antiserum. Immune complexes were collected using protein A-Sepharose and incubated with 600 U of BAP for 3 h or mock treated, and the proteins were resolved by SDS-PAGE and visualized by autoradiography. ¹⁴C low-molecularmass markers are indicated on the left (lane M). The results indicate that the phosphorylation-induced change in mobility on the SDS gel is due to the presence of aspartic acid residues at positions 151 and 153. (B) An experiment was performed as described for panel A to compare Wt Rex to mutant M17. The results indicate that the p26*rex* conformation of mutant M17 is the result of phosphorylation.

FIG. 8. Detection of single phosphorylation mutants with mutations at residues 151 and 153 in 293 T cells. Transfection, immunoprecipitation, and SDS-PAGE analysis were performed as described in the legend to Fig. 1. The various Rex mutants analyzed are indicated. The data suggest that serine 151 is more important than serine 153 for the phosphorylation-induced mobility shift from p24*rex* to p26*rex*.

present. We speculate that the concentration of phosphorylated Rex is dependent on environmental stimuli and the balance of highly regulated cellular kinase and phosphatase activities.

We propose a model for the role of phosphorylation and function of Rex-2 consistent with the current literature and our experimental data (Fig. 11). The initial Rex translation product, p24*rex*, found only in the cytoplasm, is phosphorylated at a currently unidentified serine(s), resulting in an active p26*rex*

FIG. 9. Rex-2 functional assay for single phosphorylation mutants with mutations at residues 151 and 153. The methods used are described in the legend to Fig. 3. Wild-type (Wt) Rex and the various Rex mutants analyzed are indicated. Error bars indicate standard deviations. Significance relative to the results for Wt Rex was determined by the Student *t* test; a value that is statistically different is indicated by an asterisk.The results suggest that serine 151 is more important than serine 153 in Rex function.

FIG. 10. 2D phosphoamino acid analysis for the wild type and threonine mutants. 293 T cells were transfected with $25 \mu g$ of wild-type Rex or the Rex threonine mutant. At 24 h posttransfection, cells were metabolically labeled using 2 mCi of $[^{32}P_1]$, and cell lysates were made as described in Materials and Methods. Transfected cell lysates were immunoprecipitated using anti-Rex antiserum, and proteins were transferred to an Immobilon-P membrane. The band corresponding to p26*rex* was cut out of the membrane and digested with 5.7 M HCl. 2D phosphoamino acid analysis was done on thin-layer cellulose plates in the first dimension at pH 1.9 followed by the second dimension perpendicular to the first at pH 3.4 as indicated in Materials and Methods. The data indicate that residues 151 and/or 153 are phosphorylated in vivo.

unstable intermediate. Several lines of evidence indicate that Rex is phosphorylated on at least one residue in addition to serines 151 and/or 153. First, tryptic digestion of in vivo $^{32}P_1$. labeled $p26^{rex}$ revealed multiple $^{32}P_i$ -incorporating peptides (24). However, the functional relevance of these phosphorylation sites has not been elucidated. Second, in this report we show by 2D phosphoamino acid analysis that the threonine mutant (S151T,S153T) still contains significant levels of serine phosphorylation. Last, a reduced amount of p26*rex* is still detected in the S151A,S153A mutant and shows 30 to 40% the functional activity of wild-type Rex. We propose that the p26*rex* intermediate is unstable and is subject to dephosphorylation (returning to the p24*rex* conformation) or subsequent phosphorylation at serines 151 and/or 153, which is required for the optimal function of Rex-2. This further phosphorylation at residues 151 and/or 153 may stabilize the p26*rex* conformation, possibly rendering it more resistant to phosphatases and de-

FIG. 11. Model for Rex-2 phosphorylation and function. p24*rex* is the primary Rex-2 translation product that is initially phosphorylated on an as-yet-unidentified serine(s), resulting in an unstable, but functional p26*rex* intermediate. This intermediate can now be subsequently phosphorylated on serines 151 and/or 153, resulting in a functional, stable p26*rex* form.

phosphorylation. Alanine substitutions at positions 151 and/or 153 (reduced p26*rex*) likely result in the destabilization of p26*rex*, since it cannot be further phosphorylated and thus is more sensitive to dephosphorylation, pushing the equilibrium toward the inactive p24*rex* form. The replacement of serines 151 and/or 153 with phosphomimetic aspartic acid locks the protein in the p26*rex* conformation, consistent with an irreversible equilibrium shift toward the stable and active p26*rex* form. Thus far, we have not been able to identify another phosphorylation site(s) critical for function. However, one possible candidate is serine 88. Our results indicate that mutant M9 (S88A,T90A) is nonfunctional and migrates as a single unphosphorylated protein (Fig. 2, lane M9, and data not shown).

There are several reports investigating the role of phosphorylation in the function of the HTLV Rex protein or the functionally analogous HIV Rev protein. Recently, Fouts et al. demonstrated that phosphorylation is required for recombinant HIV-1 Rev protein to enter rapidly into an efficient RNA binding state (19). The investigators also mapped the phosphorylation sites (Ser-54 and Ser-56) to be within the multimerization domain and showed that phosphorylation does not affect multimerization (19). Interestingly, this phosphorylation sequence is not conserved in the less pathogenic HIV-2. Studies of HTLV-1 Rex phosphorylation have revealed three phosphorylation sites, corresponding to Ser-70, Thr-174, and Ser-177 (1). Again, detailed functional studies of mutants to test the biological significance of phosphorylation and Rex function have not been performed. However, treatment of HTLV-1 infected T cells with protein kinase inhibitor H-7 results in a decreased level of Rex-regulated viral unspliced *gag*-*pol* mRNA, corresponding to reduced in vivo phosphorylation of Rex, suggesting a role for protein kinase C (2).

Amino acid sequence analysis of Rex-2 reveals that serine 151 falls in a predicted consensus site for phosphorylation by casein kinase 1, $S_p/T_p-X_{2-3}-S/T-X$ (28, 29). HIV-1 Rev has recently been shown to be phosphorylated on Ser-5 and Ser-8 both in vitro and in vivo by casein kinase 2, and this phosphorylation is important for its function (32). Thus, identification of cellular kinases phosphorylating Rex-2 will be critical to understanding the control of Rex activity in the HTLV life cycle and may identify distinct differences between HTLV-1 and HTLV-2.

In conclusion, our data provide the first direct evidence that phosphorylation is critical for the function of Rex-2. One implication of this finding is that HTLV-2 gene expression is regulated at the cellular level. A virus such as HTLV that encodes its own regulatory genes would be better able to adapt if it could respond to regulatory signals of the cells it infects. Therefore, the dependence of Rex function on phosphorylation provides an additional level of replication control and might better allow the virus to escape the immune pressures of the infected host.

ACKNOWLEDGMENTS

We thank Kathleen Boris-Lawrie and Michael Lairmore for critical comments. We also thank Tim Vojt for preparation of the figures.

This work was supported by a grant from the National Institutes of

Health (CA 59581).

REFERENCES

1. **Adachi, Y., T. D. Copeland, C. Takahashi, T. Nosaka, A. Ahmed, S. Oroszlan, and M. Hatanaka.** 1992. Phosphorylation of the Rex protein of human T-cell leukemia virus type I. J. Biol. Chem. **267:**21977–21981.

- 2. **Adachi, Y., T. Nosaka, and M. Hatanaka.** 1990. Protein kinase inhibitor H-7 blocks accumulation of unspliced mRNA of human T-cell leukemia virus type I (HTLV-II). Biochem. Biophys. Res. Commun. **169:**469–475.
- 3. **Akagi, T., H. Ono, and K. Shimotohno.** 1996. Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: possible involvement of Tax1 in the altered expression of cyclin D2, p18Ink4, and p21Waf1/Cip1/Sdi1. Oncogene **12:**1645–1652.
- 4. **Armstrong, A. P., A. A. Franklin, M. N. Henbogaard, H. A. Giebler, and J. K. Nyborg.** 1993. Pleiotropic effect of the human T-cell leukemia virus Tax protein on the DNA binding activity of eukaryotic transcription factors. Proc. Natl. Acad. Sci. USA **90:**7303–7307.
- 5. **Bakker, A. L. X., C. T. Ruland, D. W. Stephens, A. C. Black, and J. D. Rosenblatt.** 1996. Human T-cell leukemia virus type 2 Rex inhibits premRNA splicing in vitro at an early stage of spliceosome formation. J. Virol. **70:**5511–5518.
- 6. **Ballaun, C., G. R. Farrington, M. Dobrovnik, J. Rusche, J. Hauber, and E. Bohnlein.** 1991. Functional analysis of human T-cell leukemia virus type I Rex-response element: direct RNA binding of Rex protein correlates with in vivo binding activity. J. Virol. **65:**4408–4413.
- 7. **Barber, J. R., and I. M. Verma.** 1987. Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol. Cell. Biol. **7:**2201–2211.
- 8. **Bex, F., K. Murphy, R. Wattiez, A. Burny, and R. B. Gaynor.** 1999. Phosphorylation of the human T-cell leukemia virus type 1 transactivator Tax on adjacent serine residues is critical for Tax activation. J. Virol. **73:**738–745.
- 9. **Black, A., I. S. Chen, S. Arrigo, C. T. Ruland, T. Allogiamento, E. Chin, and J. D. Rosenblatt.** 1991. Regulation of HTLV-II gene expression by Rex involves positive and negative cis-acting elements in the $5'$ long terminal repeat. Virology **181:**433–444.
- 10. **Bockus, B. J., and B. Schaffhausen.** 1987. Phosphorylation of polyomavirus large T antigen: effects of viral mutations and cell growth state. J. Virol. **61:**1147–1154.
- 11. **Boehm, A. K., J. A. Stawhecher, O. J. Semmes, P. E. Jankowski, R. Lewis, and S. H. Hinrichs.** 1999. Analysis of potential phophorylation sites in human T cell leukemia virus type 1 Tax. J. Biomed. Sci. **6:**206–212.
- 12. **Bogerd, H., and W. C. Greene.** 1993. Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo. J. Virol. **67:**2496–2502.
- 13. **Bogerd, H. P., L. S. Tiley, and B. R. Cullen.** 1992. Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element. J. Virol. **66:**7572–7575.
- 14. **Cann, A. J., Y. Koyanagi, and I. S. Y. Chen.** 1988. High efficiency transfection of primary human lymphocytes and studies of gene expression. Oncogene **3:**123–128.
- 15. **Chen, I. S. Y., D. J. Slamon, J. D. Rosenblatt, N. P. Shah, S. G. Quan, and W. Wachsman.** 1985. The *x* gene is essential for HTLV replication. Science **229:**54–58.
- 16. **Ciminale, V., L. Zotti, D. M. D'Agostino, and L. Chieco-Bianchi.** 1997. Inhibition of human T-cell leukemia virus type 2 Rex function by truncated forms of Rex encoded in alternatively spliced mRNAs. J. Virol. **71:**2810– 2818.
- 17. **Cullen, B. R.** 1992. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol. Rev. **56:**375–394.
- 18. **Elfgang, C., O. Rosorius, L. Hofer, H. Jaksche, J. Hauber, and D. Bevec.** 1999. Evidence for specific nucleocytoplasmic transport pathways used by leucine-rich nuclear export signals. Proc. Natl. Acad. Sci. USA **96:**6229–6234.
- 19. **Fouts, D. E., H. L. True, K. A. Cengel, and D. W. Celander.** 1997. Sitespecific phosphorylation of the human immunodeficiency virus type-1 Rev protein accelerates formation of an efficient RNA-binding conformation. Biochemistry **36:**13256–13262.
- 20. **Grassmann, R., S. Berchtolds, C. Aepinus, C. Ballaun, E. Bohnlein, and B. Fleckenstein.** 1991. In vitro binding of human T-cell leukemia virus Rex proteins to the Rex-response element of viral transcripts. J. Virol. **65:**3721– 3727.
- 21. **Green, P. L., and I. S. Y. Chen.** 1994. Molecular features of the human T-cell leukemia virus: mechanisms of transformation and leukemogenicity, p. 227– 311. *In* J. A. Levy (ed.), The Retroviridae, vol. 3. Plenum Press, New York, N.Y.
- 22. **Green, P. L., Y. Xie, and I. S. Y. Chen.** 1990. The internal methionine codons of the human T-cell leukemia virus type II *rex* gene are not required for $p24^{rev}$ production or virus replication and transformation. J. Virol. **64:4914** production or virus replication and transformation. J. Virol. 64:4914– 4921.
- 23. **Green, P. L., Y. Xie, and I. S. Y. Chen.** 1991. The Rex proteins of human T-cell leukemia virus type II differ by serine phosphorylation. J. Virol. **65:** 546–550.
- 24. **Green, P. L., M. T. Yip, Y. Xie, and I. S. Y. Chen.** 1992. Phosphorylation regulates RNA binding by the human T-cell leukemia virus Rex protein. J. Virol. **66:**4325–4330.
- 25. **Hammes, S. R., and W. C. Greene.** 1993. Multiple arginine residues within the basic domain of HTLV-I Rex are required for specific RNA binding and function. Virology **193:**41–49.
- 26. **Hataka, Y., T. Umemoto, S. Matsushita, and H. Shida.** 1998. Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of human T-cell leukemia virus type 1. J. Virol. **72:**6602–6607.
- 27. **Kim, J. H., P. A. Kaufman, S. M. Hanly, L. T. Rimsky, and W. C. Greene.** 1991. Rex transregulation of human T-cell leukemia virus type II gene expression. J. Virol. **65:**405–414.
- 28. **Kreegipuu, A., N. Blom, and S. Brunak.** 1999. PhosphoBase, a database of phosphorylation sites: release 2.0. Nucleic Acids Res. **27:**237–239.
- 29. **Kreegipuu, A., N. Blom, S. Brunak, and J. Jarv.** 1998. Statistical analysis of protein kinase specificity determinants. FEBS Lett. **430:**45–50.
- 30. **Kusuhara, K., M. Anderson, S. M. Pettiford, and P. L. Green.** 1999. Human T-cell leukemia virus type 2 Rex protein increases stability and promotes nuclear to cytoplasmic transport of *gag/pol* and *env* RNAs. J. Virol. **73:**8112– 8119.
- 31. **Madore, S. J., L. S. Tiley, M. H. Malim, and B. R. Cullen.** 1994. Sequence requirements for Rev multimerization in vivo. Virology **202:**186–194.
- 32. **Marin, O., S. Sarno, M. Boschetti, M. A. Pagano, F. Meggio, V. Ciminale, D. M. D'Agostino, and L. A. Pinna.** 2000. Unique features of HIV-1 Rev protein phosphorylation by protein kinase $CK2$ ('casein kinase-2') FEBS Lett. **481:**63–67.
- 33. **Michael, W. M., M. Choi, and G. Dreyfuss.** 1995. A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway. Cell **83:**415–422.
- 34. **Nosaka, T., H. Siomi, Y. Adachi, M. Ishibashi, S. Kubota, M. Maki, and M. Hatanaka.** 1989. Nucleolar targeting signal of human T-cell leukemia virus type I Rex-encoded protein is essential for cytoplasmic accumulation of unspliced viral mRNA. Proc. Natl. Acad. Sci. USA **86:**9798–9802.
- 35. **Ohta, M., H. Nyunoya, H. Tanaka, T. Okamoto, T. Akagi, and K. Shimotohno.** 1988. Identification of a *cis*-regulatory element involved in accumulation of human T-cell leukemia virus type II genomic mRNA. J. Virol. **62:**4445–4451.
- 36. **Olsen, H. S., A. W. Cochrane, P. J. Dillon, C. M. Nalin, and C. A. Rosen.** 1990. Interaction of the human immunodeficiency virus type 1 Rev protein with a structured region in env mRNA is dependent on multimer formation mediated through a basic stretch of amino acids. Genes Dev. **4:**1357–1364.
- 37. **Palmeri, D., and M. H. Malim.** 1996. The human T-cell leukemia virus type 1 posttranscriptional *trans*-activator Rex contains a nuclear export signal. J. Virol. **70:**6442–6445.
- 38. **Ressler, S., G. F. Morris, and S. J. Marriott.** 1997. Human T-cell leukemia virus type 1 Tax transactivates the human proliferating cell nuclear antigen promoter. J. Virol. **71:**1181–1190.
- 39. **Robek, M. D., and L. Ratner.** 1999. Immortalization of $CD4^+$ and $CD8^+$ T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J. Virol. **73:**4856–4865.
- 40. **Rosenblatt, J. D., A. J. Cann, D. J. Slamon, I. S. Smalberg, N. P. Shah, J. Fujii, W. Wachsman, and I. S. Y. Chen.** 1988. HTLV-II trans-activation is regulated by two overlapping nonstructural genes. Science **240:**916–919.
- 41. **Ross, T. M., S. M. Pettiford, and P. L. Green.** 1996. The *tax* gene of human T-cell leukemia virus type 2 is essential for transformation of human T lymphocytes. J. Virol. **70:**5194–5202.
- 42. **Shima, H., M. Takano, K. Shimotohno, and M. Miwa.** 1986. Identification of p26xb and p24xb of human T-cell leukemia virus type II. FEBS Lett. **209:** 289–294.
- 43. **Siomi, H., H. Shida, S. H. Nam, T. Nosaka, M. Maki, and M. Hatanaka.** 1988. Sequence requirements for nucleolar localization of human T-cell leukemia virus type I pX protein which regulates viral RNA processing. Cell **55:**197–209.
- 44. **Smith, C. L., C. Debouck, M. Rosenberg, and J. S. Culp.** 1989. Phosphorylation of serine residue 89 of human adenovirus E1A proteins is responsible for their characteristic electrophoretic mobility shifts, and its mutation affects biological function. J. Virol. **63:**1569–1577.
- 45. **Trejo, S. R., W. E. Fahl, and L. Ratner.** 1996. c-sis/PDGF-B promoter transactivation by the Yax protein of human T-cell leukemia virus type 1. J. Biol. Chem. **271:**14584–14590.
- 46. **Volkman, B. F., D. Lipson, D. E. Wemmer, and D. Kern.** 2001. Two-state allosteric behavior in a single-domain signaling protein. Science **291:**2429– 2433.
- 47. **Wano, Y., M. Feinberg, J. B. Hosking, H. Bogerd, and W. C. Greene.** 1988. Stable expression of the HTLV-I Tax protein in human T-cells activates specific cellular genes involved in growth. Proc. Natl. Acad. Sci. USA **85:** 9733–9737.
- 48. **Weichselbraun, I., J. Berger, M. Dobrovnik, H. Bogerd, R. Grassmann, W. C. Greene, J. Hauber, and E. Bohnlein.** 1992. Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for *trans* dominance. J. Virol. **66:**4540–4545.
- 49. **Yip, M. T., W. S. Dynan, P. L. Green, A. C. Black, S. J. Arrigo, A. Torbati, S. Heaphy, C. Ruland, J. D. Rosenblatt, and I. S. Y. Chen.** 1991. Human T-cell leukemia virus (HTLV) type II Rex protein binds specifically to RNA sequences of the HTLV long terminal repeat but poorly to the human immunodeficiency virus type 1 Rev-responsive element. J. Virol. **65:**2261– 2272.